Co‐occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. Issue 4 (20th May 2018)

• Record Type: Journal Article
• Authors: Kehrer‐Sawatzki, Hildegard; Kordes, Uwe; Seiffert, Simone; Summerer, Anna; Hagel, Christian; Schüller, Ulrich; Farschtschi, Said; Schneppenheim, Reinhard; Bendszus, Martin; Godel, Tim; Mautner, Victor‐Felix
• Is Part Of: Molecular genetics & genomic medicine. Volume 6:Issue 4(2018)
• Page Start: 627
• Page End: 637
• Publication Date: 2018-05-20
• Subjects: atypical teratoid/rhabdoid tumor -- deletion breakpoint -- RTPS1 -- schwannomatosis -- SMARCB1 gene; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.412
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Background: The clinical phenotype associated with germline SMARCB1 mutations has as yet not been fully documented. It is known that germline SMARCB1 mutations may cause rhabdoid tumor predisposition syndrome (RTPS1) or schwannomatosis. However, the co‐occurrence of rhabdoid tumor and schwannomas in the same patient has not so far been reported. Methods: We investigated a family with members harboring a germline SMARCB1 deletion by means of whole‐body MRI as well as high‐resolution microstructural magnetic resonance neurography (MRN). Breakpoint‐spanning PCRs were performed to characterize the SMARCB1 deletion and its segregation in the family. Results: The index patient of this family was in complete continuous remission for an atypical teratoid/rhabdoid tumor (AT/RT) treated at the age of 2 years. However, at the age of 21 years, she exhibited paraparesis of her legs and MRI investigations revealed multiple intrathoracic and spinal schwannomas. Breakpoint‐spanning PCRs indicated that the germline deletion segregating in the family encompasses 6.4‐kb and includes parts of SMARCB1 intron 7, exons 8–9 and 3.3‐kb located telomeric to exon 9 including the SMARCB1 3′ UTR. The analysis of sequences at the deletion breakpoints showed that the deletion has been caused by replication errors including template‐switching. The patient had inherited the deletion from her 56‐year‐old healthy mother who did not exhibit schwannomas or other tumors as determined by whole‐body MRI. However, MRN of the peripheral nerves of the mother's extremities revealed multiple fascicular microlesions which have been previously identified as indicative of schwannomatosis‐associated subclinical peripheral nerve pathology. Conclusion: The occurrence of schwannomatosis‐associated clinical symptoms independent of the AT/RT as the primary disease should be considered in long‐term survivors of AT/RT. Furthermore, our investigations indicate that germline SMARCB1 mutation carriers not presenting RTs or schwannomatosis‐associated clinical symptoms may nevertheless exhibit peripheral nerve pathology as revealed by MRN. Abstract : Our findings indicate that long‐term survivors of AT/RT harboring germline SMARCB1 mutations should be surveilled for the occurrence of schwannomatosis‐associated clinical symptoms which are independent of the AT/RT as the primary disease. Furthermore, our investigations indicate that germline SMARCB1 mutation carriers not presenting rhabdoid tumors or schwannomatosis‐associated clinical symptoms may nevertheless exhibit peripheral nerve pathology as revealed by MRN.